EX-10.2



 EXHIBIT 10.2 

AMENDMENT to 
 EMPLOYMENT
AGREEMENT 
 This Amendment (the “Amendment”), dated October 6, 2016, amends that certain Employment Agreement
(“Agreement”) made and entered into effective as of February 7, 2015 (“Effective Date”) by and between CoLucid Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Matthew Dallas
(“Executive”). Capitalized terms used herein and not otherwise defined shall have the meanings set forth in the Agreement. 

Recitals 
 A. The
Company desires to continue to employ Executive, and Executive desires to continue to be employed by the Company. 
 B. The Company and
Executive desire to amend the terms of the Agreement. 
 Agreement 

NOW, THEREFORE, in consideration of the foregoing and the mutual promises set forth in this Agreement, and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and Executive agree as follows: 
  

	 	1.	Section 7.12 of the Agreement is hereby deleted and replaced in its entirety with the following: 

  

	 	7.12.	Parachute Payment Limitation 

 (a) Notwithstanding any other provision of
this Agreement or any other plan, arrangement or agreement to which the Executive is subject or a party to the contrary, if any of the payments or benefits provided or to be provided by the Company to the Executive or for the Executive’s
benefit pursuant to the terms of this Agreement or otherwise (“Covered Payments”) constitute parachute payments (“Parachute Payments”) within the meaning of Section 280G of the Internal Revenue Code of 1986, as amended (the
“Code”), and would, but for this Section 7.13, be subject to the excise tax imposed under Section 4999 of the Code (or any successor provision thereto) or any similar tax imposed by state or local law and any interest or
penalties with respect to such taxes (collectively, the “Excise Tax”), then the Covered Payments shall be payable either (i) in full or (ii) reduced to the minimum extent necessary to ensure that no portion of the Covered
Payments is subject to the Excise Tax, whichever of the foregoing clauses (i) or (ii) results in the Executive’s receipt on an after-tax basis of the greatest amount of payments and benefits after taking into account the applicable
federal, state, local and foreign income, employment and excise taxes (including the Excise Tax). 
 (b) Any such reduction
shall be made in accordance with Section 409A of the Code and the following: (i) the Covered Payments which do not constitute deferred compensation subject to Section 409A of the Code shall be reduced first, and (ii) Covered
Payments that are cash payments shall be reduced before non-cash payments, and Covered Payments to be made on a later payment date shall be reduced before payments to be made on an earlier payment date. 

(c) If, notwithstanding the initial application of this Section 7.13, the Internal Revenue Service determines that any
Covered Payment constitutes an “excess parachute payment” (as defined by Section 280G(b) of the Code), this Section 7.13 will be reapplied based on the Internal Revenue Service’s determination, and the Executive will be
required to promptly repay the portion of the Covered Payments required to avoid imposition of the Excise Tax together with interest at the applicable federal rate (as defined in Section 7872(f)(2)(A) of the Code) from the date of the
Executive’s receipt of the excess payments until the date of repayment. 







 (d) Any determination required under this Section 7.13 shall be made in
writing in good faith by the accounting firm which was the Company’s independent auditor immediately before the Change in Control (the “Accountants”), which shall provide detailed supporting calculations to the Company and the
Executive as requested by the Company or the Executive. The Company and the Executive shall provide the Accountants with such information and documents as the Accountants may reasonably request in order to make a determination under this
Section 7.13. The Company shall be responsible for all fees and expenses of the Accountants. 
 2.     This
Amendment, together with the Agreement, represents the entire understanding and agreement between the parties hereto with respect to the subject matter hereof and supersedes all prior oral and written and all contemporaneous oral negotiations,
commitments and understandings between such parties. This Amendment may not be modified or amended except by a written agreement duly executed by both parties hereto. 

IN WITNESS WHEREOF, Executive and the Company have executed this Amendment, intending it to be effective as of the date first written above.

  

							
	COMPANY:	 		 	EXECUTIVE:
			
	COLUCID PHARMACEUTICALS, INC.	 		 	MATTHEW DALLAS
				
	By:	 	/s/ Thomas P. Mathers	 		 	/s/ Matthew Dallas
		 	Thomas P. Mathers, Chief Executive Officer	 		 	Matthew Dallas